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Abstract
 Background and Aims: The National Cancer Screening Program (NCSP) for liver cancer was initiated 
in 2003 in Korea. The objective of this study was to evaluate the participation rate of the program and to 
provide preliminary information on its results based on data collected by the NCSP in 2009.  Methods: The 
target population of the NCSP for liver cancer in 2009 was comprised of 373,590 adults aged ≥40 years at high 
risk for liver cancer. Participation rates and positivity rates were assessed in this population. Multivariate 
logistic regression analysis was performed to determine the factors associated with participation in the NCSP 
for liver cancer. Results: The overall participation rate was 37.9% and 1,126 participants were positive at 
screening. The highest participation rates were observed in women, those in their 60s, National Health 
Insurance beneficiaries, and individuals positive for hepatitis B surface antigen. Positivity rates for men, 
those in their 70s, Medical Aid Program recipients and individuals with liver cirrhosis were the highest in 
the respective categories of gender, age, health insurance type, and risk factor for liver cancer.  Conclusions: 
The participation rates of the NCSP for liver cancer are still low, despite the fact that the program targets a 
high-risk group much smaller than the general population. Efforts to facilitate participation and to reduce 
disparities in liver cancer screening among Korean men and women are needed. These results provide 
essential data for evidence-based strategies for liver cancer control in Korea.
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Introduction
	 Liver	cancer	is	the	fifth	most	common	cancer	in	men	
(16.0 per 100,000, 7.9% of the total cancer burden) and 
the	seventh	in	women	(6.0	per	100,000,	6.5%	of	the	total	
cancer burden) worldwide (Ferlay et al., 2010). Because 
of	its	high	fatality	(overall	ratio	of	mortality	to	incidence	
of	0.93),	 liver	cancer	is	 the	third	most	common	cause	
of cancer death worldwide (Ferlay et al., 2010). There 
are	marked	geographic	 variations	 in	 the	 incidence	 of	
liver	cancer,	with	more	than	80%	of	cases	occurring	in	
Asia	and	Africa	(Boyle	and	Levin,	2008).	Although	the	
incidence of liver cancer in Korea has declined over the 
last	decade,	it	is	still	the	fourth	most	common	cancer	in	
Korean	men	(40.2	per	100,000)	and	 the	seventh	most	
common	cancer	 in	Korean	women	(10.8	per	100,000)	
(Jung et al., 2010). Moreover, liver cancer is the second 
most	common	cause	of	cancer	death	in	Korea	(Ministry	
of Health & Welfare and National Cancer Center, 2010).
The carcinogenic effect of chronic infection with hepatitis 
B	and	C	viruses	(HBV,	HCV)	in	liver	cancer	development	
has	 been	well	 demonstrated	 by	 epidemiological	 and	
experimental	evidence	(Boyle	and	Levin,	2008).	There	
is	 a	 remarkably	 low	 incidence	of	 liver	 cancer	 among	
healthy	 individuals	 that	 have	 no	 related	 risk	 factors.	
Therefore, liver cancer screening in patients at high 
risk	 for	 progression	 has	 the	 potential	 to	 significantly	
reduce	morbidity	and	mortality.	In	China,	a	randomized	
controlled	trial	among	individuals	at	high	risk	for	liver	
cancer	reported	that	the	mortality	rate	from	primary	liver	
cancer	was	 significantly	 lower	 in	 the	 screened	group	
(83.2	per	100,000)	than	in	the	control	group	(131.5	per	
100,000)	(Zhang	et	al.,	2004).	In	Japan,	surveillance	of	
patients	with	liver	cirrhosis	permitted	the	detection	of	
much	smaller	hepatocellular	carcinomas	and	significantly	
improved	the	5-year	survival	rate	(Ando	et	al.,	2006).
 Therefore, liver cancer surveillance or screening is 
widely	practiced	and	generally	recommended	for	certain	
high-risk	groups.	The	combination	of	alpha-fetoprotein	
(AFP)	and	ultrasonography	is	commonly	recommended	
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for surveillance testing to detect liver cancer (Daniele 
et	al.,	2004).	 In	Korea,	 the	Hepatocellular	Carcinoma	
Screening/Surveillance	 Recommendations	 were	
developed by the National Cancer Center and the Korean 
Association for the Study of the Liver in 2001 (Han and 
Park,	2002).	It	recommended	AFP	and	ultrasonography	
testing	every	6	months	for	individuals	at	high	risk	for	liver	
cancer.	Based	on	this	recommendation,	the	nationwide	
liver	cancer	screening	program	was	introduced	in	2003	
as	 part	 of	 the	National	 Cancer	 Screening	 Program	
(NCSP). Currently, the NCSP provides liver cancer 
screening	services	free	of	charge	to	Medical	Aid	Program	
(MAP) recipients and National Health Insurance (NHI) 
beneficiaries	 in	 the	 lower	 50%	 income	bracket	 (Yoo,	
2008).	The	NCSP	provides	AFP	 and	ultrasonography	
testing	 for	men	 and	women	 40	 years	 of	 age	 or	 over	
with chronic HBV or HCV infection, liver cirrhosis, or 
chronic	liver	disease	of	any	cause	(Yoo,	2008).	In	the	
NCSP for liver cancer, the screening interval depends 
on an individual’s health insurance type: MAP recipients 
are	invited	every	6	months;	NHI	beneficiaries	are	invited	
every 1-2 years, according to their NHI Corporation 
routine	health	check-up	schedule.
 Although, the NCSP for liver cancer has been in 
place	 since	 2003,	 the	 participation	 rate	 remains	 low.	
According to the NCSP report, the participation rate for 
liver	cancer	screening	was	32.7%	in	2008	(Ministry	of	
Health & Welfare and National Cancer Center, 2010). 
To	maximize	 the	benefits	of	 liver	 cancer	 screening,	 a	
high	level	of	participation	and	compliance	is	required.	
However,	 relatively	 little	 is	 known	 about	 the	 factors	
associated with participation in the NCSP for liver 
cancer. Therefore, the objectives of this study were to 
assess the participation rates of the NCSP for liver cancer 
and	determine	the	factors	associated	with	participation.	
Positivity	rate	according	to	risk	factor	for	liver	cancer	
was	also	examined.
Materials and Methods
The Study population 
	 The	major	data	source	for	this	study	was	the	NCSP	
database,	which	 contains	 information	 on	 the	MAP	
recipients	and	NHI	beneficiaries	 invited	 to	participate	
in	 the	NCSP	 for	 liver	 cancer.	The	NCSP	 invites	men	
and	women	aged	40	years	and	over	at	high	risk	for	liver	
cancer.	The	NHI	Corporation	 defined	 this	 high-risk	
group as individuals who had been tested or received 
medical	 care	 for	 HBV	 or	 HCV	 infection,	 chronic	
hepatitis, chronic liver disease, or liver cirrhosis within 
the	past	2	years,	using	the	computerized	medical	claims	
database. All those in the selected target population 
receive	an	invitation	letter	from	the	NHI	Corporation	at	
the beginning of the year. 
 The population for the current study was restricted 
to	men	and	women	who	were	 invited	for	 liver	cancer	
screening through the NCSP between January 1, 2009 
and	December	 31,	 2009.	 In	 total,	 381,960	 eligible	
individuals were invited to liver cancer screening 
during	 this	 period.	Excluded	 from	 the	 analysis	were	
Table1. Target Population and Number of Participants in the NCSP for Liver Cancer, Republic of Korea, 
2009    
	 	 	 	 Target	 	 		Number	of	 							Participation	 														ORa	(95%	CI)
                Population                  Participants                          rate 
	 	 	 																	N	(%)	 																					N	(%)																									%			(95%	CI) 
Total	 373,590	(100)	 141,460	(100)	 37.9	(37.7-38.0)	
Gender    
		Male	 223,501	(59.8)	 78,160	(55.2)	 35.0	(34.8-35.2)	 1
		Female	 150,089	(40.2)	 63,300	(44.8)	 42.2	(41.9-42.4)	 1.27	(1.25-1.29)
Age (years)    
		40-49	 122,651	(32.8)	 41,802	(29.6)	 34.1	(33.8-34.4)	 1
		50-59	 130,152	(34.8)	 51,945	(36.7)	 39.9	(39.6-40.2)	 1.31	(1.29-1.33)
		60-69	 76,440	(20.5)	 34,254	(24.2)	 44.8	(44.4-45.2)	 1.64	(1.61-1.67)
		≥70	 44,347	(11.9)	 13,459	(9.5)	 30.4	(29.9-30.8)	 0.96	(0.93-0.98)
Health insurance type    
		MAP	 91,872	(24.6)	 25,963	(18.3)	 28.3	(28.0-28.6)	 1
		NHI	 281,718	(75.4)	 115,497	(81.7)	 41.0	(40.8-41.2)	 1.61	(1.59-1.64)
Area of residence    
		Rural		 50,692	(13.6)	 15,097	(10.7)	 29.8	(29.4-30.2)	 1
		Urban	 166,169	(44.5)		 63,657	(45.0)	 39.3	(38.1-38.5)	 1.40	(1.37-1.44)
		Metropolitan	 156,729	(41.9)	 62,706	(44.3)	 40.0	(39.8-40.3)	 1.47	(1.44-1.50)
Risk	factor	for	liver	cancer	 	 	 	
		HBsAg+	 88,694	(23.8)	 40,013	(28.3)	 45.1	(44.8-45.4)	 1
		Anti-HCV+	 17,227	(	4.6	)	 6,767	(	4.8	)		 39.3	(38.6-40.0)	 0.81	(0.79-0.84)
		Chronic	liver	disease	 133,841	(35.8)	 54,721	(38.7)	 40.9	(40.6-41.2)	 0.85	(0.84-0.87)
		Liver	cirrhosis	 86,836	(23.3)	 24,819	(17.5)	 28.6	(28.3-28.9)	 0.56	(0.55-0.57)
		Others	 46,722	(12.5)	 15,140	(10.7)	 32.4	(32.0-32.8)	 0.61	(0.60-0.63)
aOR,	 adjusted	 odds	 ratio;	 CI,	 confidence	 interval;	MAP,	Medical	Aid	 Program;	NHI,	National	Health	 Insurance;	HBsAg,	
hepatitis	B	surface	antigen;	anti-HCV,	antibodies	against	hepatitis	C	virus		 	
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8,370	(2.2%)	individuals	with	a	previous	diagnosis	of	
liver cancer according to the Korean National Cancer 
Incidence	 database,	 which	 contains	 95%	 of	 newly	
diagnosed	malignancies	 in	Korea	 (Won	 et	 al.,	 2009).	
Therefore,	 the	current	analysis	was	based	on	373,590	
individuals. This study was approved by the institutional 
review board of the National Cancer Center, Korea.
Data collection and measurement  
	 The	NCSP	 database	 includes	 information	 on	 the	
target population’s gender, age, health insurance type 
(MAP or NHI), area of residence, and International 
Classification	of	Disease-10	(ICD-10)	code.	Based	on	
the	ICD-10	code,	the	individuals	were	classified	into	five	
groups: hepatitis B surface antigen (HBsAg)-positive 
(HBV carriers or those with chronic HBV infection), 
antibodies against HCV (anti-HCV)-positive (HCV 
carriers or those with chronic HCV infection), chronic 
liver disease, liver cirrhosis, and others. Cases that could 
not	 be	 assigned	 a	 category	because	 of	 insufficient	 or	
unavailable	information	were	classified	as	“others”.	
The	NCSP	database	also	has	information	on	screening	
results	 and	 self-reported	questionnaires	of	 individuals	
who have participated in liver cancer screening. Overall 
screening results were reported in four categories 
(negative, benign, suspicious and other) based on AFP 
and ultrasonography results. In the analysis, a positive 
screening	 result	was	 defined	 as	 an	 overall	 result	 of	
“suspicious”.	 The	 self-reported	 questionnaire	 also	
assessed the history of liver cancer screening through 
questions	on	whether	the	participants	had	ever	undergone	
liver cancer screening, and when they underwent their 
most	 recent	 screening	 (≤6	months,	 7-12	months,	≥13	
months	 ago).	 Information	 on	 family	 history	 of	 liver	
cancer	was	also	collected,	and	included	only	immediate	
blood	relatives	(mother/father,	sister/brother,	daughter/
son, half-sister/half-brother). 
Statistical Analysis 
	 Participation	 rates	were	 analyzed	 by	 gender,	 age,	
health	insurance	type,	area	of	residence,	and	risk	factors	
for	liver	cancer.	Multivariable	logistic	regression	models	
were	fit	with	generalized	estimating	equations	to	identify	
significant	predictors	of	participation	in	 the	NCSP	for	
liver cancer (participated versus not participated). We 
also	 analyzed	 the	 screening	 history	 of	 participants	
according	to	their	risk	factors	for	liver	cancer.		
 Positivity rates for liver cancer screening were 
calculated	from	the	proportion	of	positive	cases	among	
liver cancer screening participants in 2009. The adjusted 
odds ratio (aOR) was calculated for each subcategory 
of gender, age, health insurance type, area of residence, 
history	of	liver	cancer	screening	and	family	history	of	
liver cancer. All statistical analyses were conducted using 
SAS	statistical	software	(version	9.1;	SAS	Institute	Inc.,	
Cary, North Carolina, USA).
Results 
Characteristics of the study population and participation 
rates of the NCSP for liver cancer 
 The total target population invited for liver cancer 
screening	 in	2009	was	373,590	(Table	1).	There	were	
223,501	 (59.8%)	men	 and	 150,089	 (40.2%)	women.	
Individuals	with	 chronic	 liver	 disease	were	 the	most	
frequent	 (35.8%),	 followed	 by	 HBsAg-positive	
individuals	 (23.8%),	 and	 those	with	 liver	 cirrhosis	
(23.3%).	Of	the	target	population,	141,460	participants	
underwent liver cancer screening, yielding a participation 
rate	of	37.9%	(Table	1).	Women	were	1.27	times	more	
likely	 to	 participate	 than	men,	 and	NHI	 beneficiaries	
were	1.61	 times	more	 likely	 to	 participate	 than	MAP	
recipients.	Individuals	living	in	metropolitan	areas	were	
more	likely	to	participate	than	those	living	in	rural	areas.	
Regarding	risk	factors	for	liver	cancer,	individuals	with	
liver	cirrhosis	were	less	likely	to	participate	(aOR=0.56;	
95%	CI=0.55-0.57)	than	HBsAg-positive	individuals.	
History of liver cancer screening
	 We	analyzed	history	of	liver	cancer	screening	among	
participants,	including	both	organized	and	opportunistic	
screening (Table 2). About half of the participants had 
no history of liver cancer screening. HBsAg-positive 
individuals showed the highest history of screening, 
followed by anti-HCV-positive individuals and those 
with liver cirrhosis. Overall only 6% of participants 
had undergone liver cancer screening within the past 6 
months.	
Positivity rates
	 Among	 the	 participants	 of	 liver	 cancer	 screening,	
1,126	(0.80%)	were	positive	(Table	3).	The	positivity	rate	
for	men	(1.04%)	was	more	than	twice	as	high	as	that	for	
women	(0.49%).	As	age	increased,	positivity	rates	also	
Table 2. Previous Liver Cancer Screening among Participants of the NCSP for Liver Cancer, Republic of 
Korea, 2009       
History	of	liver	 	 		 																				Risk	factor	for	liver	cancer,	N	(%)	 	 	 	        
cancer screening Total         HBsAg+      Anti-HCV+       Chronic liver disease   Liver cirrhosis       Other          p-value
Never	 71,688	(50.7)	 15,928	(39.8)	 2,971	(43.9)	 30,645	(56.0)	 12,628	(50.9)	 9,516	(62.8)	 P<0.001
≤6	months	 8,521	(6.0)	 3,855	(9.6)	 631	(9.3)	 1,998	(3.6)	 1,706	(6.9)	 331	(2.2)	
7-12	months	 22,332	(15.8)	 8,957	(22.4)	 1,245	(18.4)	 6,895	(12.6)	 3,652	(14.7)	 1,583	(10.5)	
≥13	months	 33,536	(23.7)	 9,946	(24.9)	 1,658	(24.5)	 13,070	(23.9)	 5,878	(23.7)	 2,984	(19.7)	
Unknown	 5,383	(3.8)	 1,327	(3.3)	 262	(3.9)	 2,113	(3.9)	 955	(3.8)	 726	(4.8) 
HBsAg,	hepatitis	B	surface	antigen;	anti-HCV,	antibodies	against	hepatitis	C	virus		 	 	 	
Asian Pacific Journal of Cancer Prevention, Vol 13, 2012
Dai Keun Noh et al
734
statistically	 significantly	 increased.	Among	 categories	
of	 health	 insurance	 type,	 the	 positivity	 rate	 among	
MAP	recipients	 (0.88%)	was	higher	 than	among	NHI	
recipients	 (0.78%).	According	 to	 risk	 factors	 for	 liver	
cancer, the positivity rate was highest in individuals with 
liver cirrhosis (1.39%), followed by anti-HCV-positive 
(1.09%) and HBsAg-positive (1.02%) individuals. 
Among	categories	of	area	of	residence,	positivity	rate	was	
highest	among	individuals	living	in	a	metropolitan	area;	
individuals who had undergone liver cancer screening 
within	the	past	6	months	showed	statistically	significantly	
higher positivity rates than those who had never been 
screened	 before.	Those	who	 had	 a	 family	 history	 of	
liver	cancer	also	showed	statistically	significantly	higher	
positivity rates.
Discussion
Although several studies have reported on the 
effectiveness	 of	 liver	 cancer	 screening	 in	 high-risk	
groups	(Chen	et	al.,	2002;	Zhang	et	al.,	2004;	Ando	et	
al.,	2006),	the	implementation	of	nationwide	organized	
liver	 cancer	 screening	programs	 is	 still	 controversial.	
At present, several Asian countries conduct liver cancer 
screening	programs,	but	 these	are	either	opportunistic	
screening	programs,	or	are	regional	instead	of	nationwide	
programs.	In	Korea,	the	liver	cancer	screening	program	
was initiated in 2003 because liver cancer is the third 
most	common	cause	of	cancer	death	in	the	country	after	
lung	and	stomach	cancer.	To	our	knowledge,	the	present	
study	is	the	first,	large	population-based	study	reporting	
participation rate and positivity rate in the NCSP for 
liver cancer. 
Overall	 in	 the	present	study,	approximately	37.9%	
of those invited were screened in 2009. Despite the 
increasing	 trend	 in	participation	(from	15.8%	in	2003	
to 37.9% in 2009) (Lee et al., 2010) this rate is still 
low	compared	to	the	58.2%	participation	in	a	Chinese	
scheme	 (Zhang	 et	 al.,	 2004).	 Furthermore,	 there	 is	
an apparent worldwide gap between the participation 
observed for liver cancer screening and other types of 
cancer	screening.	In	the	United	Kingdom	for	example,	
Table 3. Number of Participants and Number of Positive Cases in the NCSP for Liver Cancer, Republic of 
Korea, 2009    
	 																															Number	of	 										Number	of	 																							Positivity	 																			ORa
	 																															participants		 									positive	cases																											rates		 															(95%	CI)
	 																																				N	(%)	 																																N	(%)	 																						%	(95%	CI)	 
Total	 141,460	(100.0)	 1,126	(100.0)	 0.80	(0.75-0.84)	
Gender    
		Male	 78,160	(55.2)	 815	(72.4)	 1.04	(0.97-1.12)	 1
		Female	 63,300	(44.8)	 311	(27.6)	 0.49	(0.44-0.55)	 0.53	(0.46-0.60)
Age (years)    
		40-49	 41,802	(29.6)	 216	(19.2)	 0.52	(0.45-0.59)	 1
		50-59	 51,945	(36.7)	 430	(38.2)	 0.83	(0.75-0.91)	 1.69	(1.43-1.99)
		60-69	 34,254	(24.2)	 343	(30.4)	 1.00	(0.90-1.11)	 2.14	(1.80-2.54)
		≥70	 13,459	(9.5)	 137	(12.2)	 1.02	(0.86-1.21)	 2.51	(2.01-3.13)
Health insurance type    
		MAP	 25,963	(18.3)	 228	(20.2)	 0.88	(0.77-1.00)	 1
		NHI	 115,497	(81.7)	 898	(79.8)	 0.78	(0.73-0.83)	 0.90	(0.78-1.05)
Area of residence    
		Rural	 1,5097	(10.7)	 112	(9.9)	 0.74	(0.61-0.90)	 1
		Urban	 63,657	(45.0)	 493	(43.8)	 0.77	(0.71-0.85)	 1.18	(0.96-1.46)
		Metropolitan	 62,706	(44.3)	 521	(46.3)	 0.83	(0.76-0.91)	 1.27	(1.04-1.57)
Risk	factor	for	liver	cancer	 	 	 	
		HBsAg+	 40,013	(28.3)	 407	(36.2)	 1.02	(0.92-1.12)	 1
		Anti-HCV+	 6,767	(4.8)	 74	(6.6)	 1.09	(0.87-1.38)	 0.99	(0.77-1.27)
		Chronic	liver	disease	 54,721	(38.7)	 165	(14.6)	 0.30	(0.26-0.35)	 0.29	(0.24-0.34)
		Liver	cirrhosis	 24,819	(17.5)	 346	(20.7)	 1.39	(1.25-1.55)	 1.11	(0.96-1.30)
		Others	 15,140	(10.7)	 134	(11.9)	 0.89	(0.74-1.05)	 0.85	(0.70-1.04)
History of liver cancer screening    
		Never	 71,688	(50.7)	 497	(44.1)	 0.69	(0.63-0.76)	 1
		≤6	months	 8,521	(6.0)	 100	(8.9)	 1.17	(0.96-1.43)	 1.40	(1.12-1.74)
		7-12	months	 22,332	(15.8)	 200	(17.8)	 0.90	(0.78-1.03)	 1.14	(0.96-1.35)
		≥13	months	 33,536	(23.7)	 302	(26.8)	 0.90	(0.80-1.01)	 1.22	(1.06-1.41)
		Unknown	 5,383	(3.8)	 27	(2.4)	 0.50	(0.34-0.74)	 0.57	(0.37-0.88)
Family	history	of	liver	cancer	 	 	 	
		No	 121,336	(85.8)	 921	(81.8)	 0.76	(0.71-0.81)	 1
		Yes	 11,879	(8.4)	 135	(12.0)	 1.14	(0.96-1.35)	 1.44	(1.19-1.73)
		Unknown	 8,245	(5.8)	 70	(6.2)	 0.85	(0.67-1.08)	 1.31	(1.00-1.72)
aOR,	 adjusted	 odds	 ratio;	 CI,	 confidence	 interval;	MAP,	Medical	Aid	 Program;	NHI,	National	Health	 Insurance;	HBsAg,	
hepatitis	B	surface	antigen;	anti-HCV,	antibodies	against	hepatitis	C	virus.		 	
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where	nationwide	organized	screening	programs	have	
been	implemented,	73.7%	of	women	aged	45-74	years	
underwent	 breast	 cancer	 screening	by	mammography	
in	 2008-2009	 (NHS	Cancer	 Screening	Programmes,	
2010a),	 and	 78.9%	 of	 women	 aged	 25-64	 years	
underwent	 cervical	 cancer	 screening	 by	 Pap	 smear	
in	 2009-2010	 (NHS	Cancer	 Screening	Programmes,	
2010b). Although the target population for liver cancer 
screening	in	Korea	is	restricted	to	a	smaller,	high-risk	
population,	the	participation	rate	is	still	much	lower	than	
that for breast or cervical cancer screening, which targets 
the	larger	general	population.	There	may	be	many	reasons	
to explain why only about one-third of individuals 
participated in liver cancer screening in the present study. 
Low	awareness	of	the	existence	of	the	program	and	the	
necessity	for	early	detection	of	liver	cancer	among	the	
high-risk	population	may	be	a	factor.	It	is	also	possible	
that	 individuals	 at	high	 risk	 for	 liver	 cancer	 routinely	
visit	hospitals	or	clinics	for	health	check-ups	instead	of	
utilizing	the	screening	program.	In	the	NCSP	for	liver	
cancer,	screening	is	performed	at	a	clinic	or	hospital	that	
has been designated as a liver cancer screening unit, and 
those who are invited for screening should visit one of 
these designated liver cancer screening units instead of 
their	usual	care	provider.	The	lack	of	a	close	relationship	
or continuous connection between a physician in a liver 
cancer screening unit and participants, which does exist 
between	patients	 and	 their	 usual	 care	 provider,	might	
have affected the low participation rate. 
In	 the	current	 study,	women,	 individuals	 aged	60-
69 years, and NHI beneficiaries were significantly 
more	likely	to	participate	in	the	NCSP	for	liver	cancer.	
Specifically,	 individuals	 aged	 70	 years	 or	 over	were	
less	 likely	 to	participate	 than	 those	aged	40-69	years.	
In	the	NCSP	for	liver	cancer,	there	is	no	age	limit	for	
screening. All people in the target population receive 
an	 invitation	 letter	 from	 the	NHI	Corporation	 at	 the	
beginning of the year. Therefore, the lower participation 
rate	 among	 individuals	 aged	 70	 or	 over	may	 be	 due	
to	a	hesitancy	to	follow	the	recommendation	for	 liver	
cancer	screening.	Also,	it	may	be	more	difficult	for	the	
elderly to understand the need to undergo liver cancer 
screening.	MAP	recipients	were	also	less	likely	than	NHI	
beneficiaries	to	participate	in	the	NCSP	for	liver	cancer,	
despite the fact that screening services are free of charge 
in the NCSP. Gaps in the participation rate between MAP 
recipients	and	NHI	beneficiaries	may	reflect	a	decreased	
awareness	 among	MAP	 recipients	 about	 the	 expected	
benefits	 of	 liver	 cancer	 screening.	A	 previous	 study	
conducted	in	Korea	reported	that	socioeconomic	status	
is	highly	related	to	liver	cancer	incidence	and	mortality	
(Kim	et	al.,	2008).	Therefore,	it	is	important	to	increase	
the participation of MAP recipients in liver cancer 
screening to decrease the burden of liver cancer in Korea. 
The factors associated with liver cancer screening 
in	the	current	study	were	similar	to	those	found	in	other	
types	of	cancer	screening	(Farmer	et	al.,	2008;	Meissner	
et al., 2006). However, the target population of liver 
cancer	screening	does	differ	from	that	of	other	types	of	
cancer screening, as liver cancer screening targets the 
high-risk	population,	 i.e.,	 patients	with	HBV	or	HCV	
infection, chronic hepatitis, chronic liver disease, or 
liver cirrhosis. The participation rate varied between 
individuals	with	different	risk	factors	for	 liver	cancer.	
Generally,	 compliance	was	 better	 in	 individuals	with	
liver	 cirrhosis	 than	 in	 asymptomatic	HBV	 carriers	
(Benvegnu	et	al.,	1994;	Colombo	et	al.,	1989;	Kato	et	
al.,	 1994;	Oka	 et	 al.,	 1994).	However,	 in	 the	 current	
study,	individuals	with	liver	cirrhosis	were	less	likely	to	
participate	(aOR=0.56;	95%	CI=0.55-0.57)	than	HBsAg-
positive	 individuals.	This	may	be	partly	 explained	by	
the	 fact	 that	 individuals	with	 liver	 cirrhosis	 are	more	
likely	to	use	medical	services	than	screening	services,	
as liver cirrhosis is the highest stage of progression 
in	terms	of	natural	history	of	disease.	As	we	analyzed	
only NCSP data, we could not consider liver cancer 
screening/surveillance occurring through private health 
examination	or	in	the	private	medical	sector.
An	important	issue	related	to	the	early	detection	of	
cancer is the extent to which patients continue to use 
screening	services	after	an	initial	examination.	In	case	of	
liver cancer screening, reported screening intervals vary 
from	3	to	12	months	(Han	and	Park,	2002).	However,	
there	is	no	study	that	directly	addresses	the	question	of	
how	frequently	screening	should	be	performed.	Although	
the	NCSP	recommends	a	screening	interval	of	6	months,	
which	is	based	on	tumor	doubling	time,	our	study	revealed	
relatively few participants that had undergone regular 
liver	 cancer	 screening.	Among	 participants	 in	 2009,	
only 6% had undergone liver cancer screening within the 
past	6	months,	and	21.8	%	within	the	past	12	months.	
Furthermore,	individuals	with	liver	cirrhosis	were	less	
likely	to	have	undergone	liver	cancer	screening	within	
the	framework	of	the	NCSP	for	liver	cancer,	compared	
with HBsAg-positive or anti-HCV-positive individuals. 
Among	 those	with	 liver	 cirrhosis,	 the	 proportion	 of	
MAP recipients was relatively high (data not shown), 
suggesting that people who do not undergo screening 
are	generally	from	less	affluent	socioeconomic	groups	
than	those	who	do	undergo	screening.	The	consequence	
of	this	could	be	poorer	health	status	among	these	less	
affluent	groups,	and	a	higher	risk	of	disease.	Therefore,	
active	intervention	that	targets	low-income	liver	cirrhosis	
patients	may	help	increase	the	liver	cancer	screening	rate.	
In	the	current	study,	male	gender	and	increasing	age	
were	also	risk	factors	for	screening	positivity	in	those	
with chronic HBV or HCV infection, liver cirrhosis, or 
chronic liver disease. The positivity rate of liver cancer 
screening	was	higher	 in	men	 (1.04%;	95%	CI=	0.97-
1.12)	than	women	(0.49%;	95%	CI=0.44-0.55),	and	as	
age increased, positivity rates for liver cancer screening 
also	increased.	According	to	risk	factors	for	liver	cancer,	
the positivity rate was highest in individuals with 
liver cirrhosis (1.39%) followed by anti-HCV-positive 
(1.09%), and HBsAg-positive (1.02%) individuals. 
Overall,	 liver	 cirrhosis	 of	 any	 etiology	 is	 the	most	
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important	risk	factor	for	liver	cancer,	as	it	represents	the	
last	stage	before	liver	cancer	(Sangiovanni	et	al.,	2004).	
Our	 study	 has	 several	 limitations.	Although	 the	
NCSP for liver cancer is a nationwide population-
based	 screening	program,	we	may	have	missed	 some	
tests	 performed	outside	 this	 framework,	 as	 the	NCSP	
does not capture tests paid for privately, or conducted 
as	 a	medical	 service	 unrelated	 to	 screening.	 Second,	
the	NCSP	database	 lacks	 details	 about	why	 a	 patient	
did not undergo screening. We were unable to explore 
the	 influence	 of	 other	 important	 correlates,	 such	 as	
individual	characteristics	(e.g.,	education	level,	income,	
availability of transportation, or of screening facilities 
in the geographic area) and psychological factors 
(e.g.,	 discomfort,	 concern	 about	 complications,	 or	
anxiety	about	the	procedure)	that	might	be	involved	in	
participation. 
Despite	these	limitations,	to	the	best	of	our	knowledge,	
this	 is	 the	 first	 population-based	 study	 to	 provide	 a	
participation rate for liver cancer screening in the 
Republic of Korea. Indeed, the low participation rate of 
liver cancer screening in Korea revealed in this study is 
worrisome.	The	NCSP	for	liver	cancer	has	been	offered	
to	the	high-risk	population	since	2003,	yet	despite	the	
reduced	target	population,	the	participation	rate	among	
these	men	and	women	is	still	disappointingly	low;	far	
lower	than	some	screening	programs	geared	toward	the	
general population. This result underscores the urgent 
need	for	interventions	to	improve	the	participation	rates	
of	 liver	 cancer	 screening.	The	 findings	 of	 the	 study	
support the critical need for increasing efforts to raise 
awareness	and	provide	more	screening	in	the	high-risk	
population. 
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